Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
$0.29
$0.15
$0.84
$10.93M1.3160,047 shs1.27 million shs
NVH
Novoheart
C$0.53
+1.9%
C$0.53
C$0.26
C$0.72
C$99.98MN/A33,593 shs23,066 shs
Veresen Inc stock logo
VSN
Veresen
C$0.00
C$11.40
C$19.07
C$5.81BN/A1.30 million shs1.15 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.00%0.00%0.00%0.00%0.00%
NVH
Novoheart
0.00%0.00%0.00%0.00%0.00%
Veresen Inc stock logo
VSN
Veresen
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NVH
Novoheart
N/AN/AN/AN/AN/AN/AN/AN/A
Veresen Inc stock logo
VSN
Veresen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
3.00
Buy$2.50∞ Upside
NVH
Novoheart
0.00
N/AN/AN/A
Veresen Inc stock logo
VSN
Veresen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A
NVH
Novoheart
C$423.50K236.08C$0.07 per share7.46C$0.12 per share4.34
Veresen Inc stock logo
VSN
Veresen
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/A
NVH
Novoheart
N/A-C$0.04N/AN/AN/AN/AN/AN/A
Veresen Inc stock logo
VSN
Veresen
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/A
NVH
Novoheart
N/AN/AN/AN/AN/A
Veresen Inc stock logo
VSN
Veresen
C$1.005.27%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/A
9.57
9.57
NVH
Novoheart
27.62
6.13
6.05
Veresen Inc stock logo
VSN
Veresen
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
12.38%
NVH
Novoheart
N/A
Veresen Inc stock logo
VSN
Veresen
N/A

Insider Ownership

CompanyInsider Ownership
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
33.10%
NVH
Novoheart
N/A
Veresen Inc stock logo
VSN
Veresen
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
1669.64 million46.59 millionNot Optionable
NVH
Novoheart
N/A188.64 millionN/ANot Optionable
Veresen Inc stock logo
VSN
Veresen
147,000314.00 millionN/ANot Optionable

Recent News About These Companies

BBC Sounds - Assignment - Available Episodes

Media Sentiment Over Time

Top Headlines

View All Headlines
Medicenna Therapeutics stock logo

Medicenna Therapeutics NASDAQ:MDNA

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Novoheart CVE:NVH

C$0.53 +0.01 (+1.92%)
As of 11/20/2020

Novoheart Holdings Inc. operates as a stem cell biotechnology company in the United States. The company offers an array of next-generation human heart tissue prototypes. It provides MyHeart platform products, including human pluripotent stem cell-derived cardiomyocytes, human ventricular cardiac anisotropic sheet assays, and human ventricular cardiac tissue strips assays. The company also offers screening and phenotyping services; and consultation services, including mapping and designing preclinical studies that involve human embryonic or induced pluripotent stem cell-derived cardiomyocytes, prototyping custom bioreactor designs, and developing custom software for streamlining of screening platforms and analysis of acquired data. Novoheart Holdings Inc. has a collaboration with AstraZeneca to develop human-specific in vitro functional model of heart failure with preserved ejection fraction. The company is based in Vancouver, Canada.

Veresen stock logo

Veresen TSE:VSN

Veresen Inc is a Canada-based energy infrastructure company that owns and operates energy infrastructure assets across North America. The Company is engaged in three principal businesses: a pipeline transportation business consists of interests in the Alliance Pipeline, the Ruby Pipeline and the Alberta Ethane Gathering System (AEGS); a midstream business, which includes a partnership interest in Veresen Midstream Limited Partnership, which owns assets in western Canada, and an ownership interest in Aux Sable, which owns a natural gas liquids (NGL) extraction facility near Chicago, and other natural gas and NGL processing energy infrastructure, and a power business consists of a portfolio of assets in Canada. The Company's segments include Pipelines, Midstream, Power and Corporate. Alliance Pipeline owns and manages an integrated, high-pressure natural gas and NGL pipeline. Ruby Pipeline is a natural gas transmission system. AEGS is an integrated pipeline system.